A Takeda quality executive demonstrates how a team of AI agents uses synthetic data to provide decision support ahead of CDMO audits.
- Closing The MES Value Gap: Why Technology Isn't The Problem
- Why Are Life Science Companies So Poorly Prepared For RIM's Future?
- CDMO Capacity Crunch: Are Biotechs Wasting Time On The Wrong CDMO?
- Why Your MES RFP Is Failing Before It Starts
- Why Dilution Gets Tricky: The Role Of Measurement Variability
- Causal Mechanism And Effect Analysis (CMEA): FMEA's Simpler, Effective Alternative
- The Stepwise Path Lilly Mapped From Paper To Digital Logbooks
GUEST COLUMNISTS
-
Closing The MES Value Gap: Why Technology Isn't The Problem
Manufacturing execution system (MES) technical maturity is rising, but adoption across manufacturing sites is uneven. Organizational readiness may hold the key.
-
Why Are Life Science Companies So Poorly Prepared For RIM's Future?
Most organizations have modernized their global regulatory information management (RIM) systems and improved data quality. Yet modernization and readiness are not the same thing.
-
CDMO Capacity Crunch: Are Biotechs Wasting Time On The Wrong CDMO?
Biotechs often default to one of two flawed instincts: pursue the biggest name in the space or go with the lowest bidder. To avoid misalignment, look at these less visible factors.
-
Why Your MES RFP Is Failing Before It Starts
Many manufacturing execution system requests for proposals fail. Not because vendors cannot deliver or the tech is immature, but because the requirements are written backward.
-
Why Dilution Gets Tricky: The Role Of Measurement Variability
Dilution's effects on downstream processes and final formulation is often understated. A statistical framework can quantify measurement uncertainty's impacts.
-
Causal Mechanism And Effect Analysis (CMEA): FMEA's Simpler, Effective Alternative
This article describes causal mechanism and effect analysis (CMEA) as an alternative to failure mode and effect analysis (FMEA) for analyzing and managing the industry’s risks.
-
The Stepwise Path Lilly Mapped From Paper To Digital Logbooks
Eli Lilly and Company started at the front lines, on the shop floor gathering operator input, when switching from paper to digital logbooks.
BIOSIMILAR WHITE PAPERS
-
Regulatory Considerations For Excipients Used In Lipid Nanoparticles
Review the regulatory classification of LNPs, liposomes, and novel excipients as well as specific requirements outlined in regulatory guidance documents and strategies to navigate emerging challenges.
-
The Role Of Extractables Data In The Adoption Of Single-Use Systems8/29/2024
Explore guidance for evaluating single-use systems for extractables and leachables, and learn how supplier-provided single-use system extractables data can save both time and resources.
-
The Evolution Of Antibody-Drug Manufacturing6/3/2024
Explore how ADC chemistry and manufacturing have evolved, the challenges this dynamic growth has created, and how CDMOs are adapting to these changes to meet customer needs, now and in the future.
-
How Lipid Nanoparticles Enable Next-Gen Delivery10/20/2025
Cell therapy’s future depends on smarter gene delivery. Learn how lipid nanoparticles offer a scalable, cell-friendly alternative to electroporation and viral vectors for manufacturing efficiency.
-
Ready To Demystify Organoids?7/1/2025
Organoids are transforming biomedical research. Explore their top applications, research workflows, key challenges, and dissociation techniques in this comprehensive guide to personalized medicine.
-
Why Biopharma Breakthroughs Aren't Moving The Market10/20/2025
Biopharma is innovating fast but falling short commercially. Reveal key ecosystem gaps and five strategic actions to help strengthen resilience, accelerate performance, and futureproof organizations.
BIOSIMILAR APP NOTES & CASE STUDIES
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Federal Budget 2026-27: Biosimilars Recognised As An Opportunity To Expand Patient Access
- IQVIA And Kexing Biopharm Expand Strategic Collaboration To Accelerate Global Biosimilar Development Using AI-Enabled Capabilities
- Globalisation 2.0 | U.S. FDA Clearance Of IND For Cetuximab Biosimilar HLX05-N
- Xbrane And Its Partner Intas Agree On Revised Financing Arrangement For Xbrane's Xdivane Development Activities
- CVS Caremark Expands Biosimilar Adoption Through Formulary Updates To Improve Affordability And Access
- Lannett Company, Lanexa Biologics And Sunshine Lake Pharma Announce FDA Approval Of LANGLARA An Interchangeable Biosimilar Of Lantus (insulin glargine)
- Xbrane Submits Ranibizumab Biosimilar Candidate To FDA
- EirGenix Advances Into CPHI Japan, Capitalizing On Market Trends To Deepen Its Strategic Footprint In Japan
NEWSLETTER ARCHIVE
- 05.14.26 -- Do Changes Signal The End Of Biosimilar Regulatory Redundancy?
- 05.07.26 -- The Business Case For Continuous Manufacturing In Biologics
- 04.30.26 -- Quantifying Single-Use Waste Produced During mAb Manufacture
- 04.16.26 -- Innovation That's Redefining Aseptic Filling
- 04.16.26 -- How Biopharma Continues To Grapple With Annex 1